<DOC>
	<DOC>NCT02836743</DOC>
	<brief_summary>To evaluate effect of slow-release melatonin (Circadin) on REM sleep behavior disorder.</brief_summary>
	<brief_title>Effect of Slow-release Melatonin (CircadinÂ®) Therapy on Idiopathic RBD: a Pilot Study</brief_title>
	<detailed_description>Investigators planned to administer low (2mg) and high (6mg) dose slow-release melatonin and the placebo for 4 weeks and evaluate Clinical Global Impression scale, RBD questionnaire, PSQI, Epworth sleepiness scale, and quality of life questionnaire (SF-36v2) before and after the treatment along with possible side effects and drug compliance.</detailed_description>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>REM Sleep Behavior Disorder</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>REM sleep behavior disorder according to ICSD3 criteria No cognitive deficit or symptom of Parkinsonism Those with written consent. who took medication (ex. clonazepam) for REM sleep behavior disorder with degenerative neurologic disorder (ex. Parkinson's disease, Multiple System Atrophy, Lewybody dementia, etc.) who took medication that can affect REM sleep behavior disorder (antidepressant: SSRI, TCA, MAOinhibitor) who is unable to answer questionnaires who have hypersensitive reaction to medications Pregnant women or breastfeeding who are diagnosed with other parasomnia disorder with severe medical disorder (severe liver failure, respiratory failure, heart failure, malignant tumor, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>REM sleep behavior disorder</keyword>
	<keyword>Melatonin</keyword>
</DOC>